🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with figures suggesting over 82 million infections per year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Global Access

As per data published in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The trial enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in many developing nations.

Clinicians treating patients have shared hope. Access to a easy-to-administer therapy of this kind is seen as a "game-changer" for public health efforts. This is viewed as essential to reduce the burden of the infection for people and to stop the proliferation of untreatable gonorrhoea around the world.